Reports Q4 revenue $8.9B, consensus $8.83B. “We had a strong close to our fiscal year, and I’m excited to see the progress we are making as our growth drivers continue to build momentum. Operationally, we translated our accelerating revenue growth into earnings leverage, as we delivered at the upper end of the commitments that we laid out a year ago,” said Geoff Martha, Medtronic (MDT) chairman and chief executive officer. “The underlying fundamentals of our business are strong, and they are getting stronger. We are now at an inflection point as we accelerate our speed of travel to higher, more profitable growth.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Medtronic to separate diabetes unit into standalone company, WSJ reports
- Medtronic Stock (MDT) Looks Poorly on Diabetes Arm Spin Off Plans
- Notable companies reporting before tomorrow’s open
- Is Medtronic Stock (MDT) a Buy Ahead of Earnings?
- Options Volatility and Implied Earnings Moves This Week, May 19 – May 22, 2025